again how many times, you just swipe your face and come back...

again how many times, you just swipe your face and come back again...

yes Australia does offer a generous R&D tax rebate (up to 43.5% for eligible entities). But claiming IMU was ‘complacent’ by launching onCARlytics in the US first shows your ignorance, do you think any serous biotech will ignore US market, the biggest and most influential in the world, may be RAC does it who cares..Imugene was targeting fast-track and Orphan Drug advantages in the U.S for Gods sake..

The foundational U.S. data needed to mature before expanding here. Now, they’re balancing global trial geography and unlocking the R&D rebate in FY26 (not FY25 the Aus spend happens in FY26). That’s a longer-term efficiency, not a short-term rebate grab, this concept is beyond you, dont even try to comprehend this..

claiming they got ‘Covid money’ and somehow lost their discipline? you seriously out of your mind, try harder if you want to learn how this works..MU raised capital during a global biotech surge — like every other ASX biotech in 2020–21 and surprisingly they remained conservative with dilution compared to peers (will not give my research on peers that costed me money)..what you don’t seem to understand is that global trial sequencing isn’t binary. U.S. trials first, Aus second, doesn’t equal failure, thats how biotechs roll..if your knowledge about clinical stage biotech is RAC and its strategy, then God help you with your investments..